Drug intelligence / Profile preview

SSGJ-709

Development stage: Phase 1
Lead developer: Shenyang Sunshine Pharmaceutical Co., LTD.
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SSGJ-709 is a bispecific antibody designed to target both **PD-1** (Programmed cell death protein 1) and **LAG-3** (Lymphocyte activation gene-3), two immune checkpoint proteins involved in the regulation of immune responses against tumors. By simultaneously inhibiting PD-1 and LAG-3, SSGJ-709 is intended to enhance the anti-tumor activity of T cells and potentially overcome resistance mechanisms associated with single checkpoint blockade. SSGJ-709 is being developed for use in patients with advanced malignant solid tumors and is currently under investigation in phase 1 clinical studies for safety, pharmacokinetics, and anti-tumor efficacy. The drug is developed by Shenyang Sunshine Pharmaceutical[1][2][6][7][9].

Other names: SSGJ-709SSGJ709SSGJ 709

Targets

LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SSGJ-709.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSGJ-709.

Explore the full profile